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Abstract
Background: Gene expression is controlled over a wide range at the transcript level through
complex interplay between DNA and regulatory proteins, resulting in profiles of gene expression
that can be represented as normal, graded, and bimodal (switch-like) distributions. We have
previously performed genome-scale identification and annotation of genes with switch-like
expression at the transcript level in mouse, using large microarray datasets for healthy tissue, in
order to study the cellular pathways and regulatory mechanisms involving this class of genes. We
showed that a large population of bimodal mouse genes encoding for cell membrane and
extracellular matrix proteins is involved in communication pathways. This study expands on
previous results by annotating human bimodal genes, investigating their correspondence to
bimodality in mouse orthologs and exploring possible regulatory mechanisms that contribute to
bimodality in gene expression in human and mouse.
Results: Fourteen percent of the human genes on the HGU133A array (1847 out of 13076) were
identified as bimodal or switch-like. More than 40% were found to have bimodal mouse orthologs.
KEGG pathways enriched for bimodal genes included ECM-receptor interaction, focal adhesion,
and tight junction, showing strong similarity to the results obtained in mouse. Tissue-specific modes
of expression of bimodal genes among brain, heart, and skeletal muscle were common between
human and mouse. Promoter analysis revealed a higher than average number of transcription start
sites per gene within the set of bimodal genes. Moreover, the bimodal gene set had differentially
methylated histones compared to the set of the remaining genes in the genome.
Conclusion:  The fact that bimodal genes were enriched within the cell membrane and
extracellular environment make these genes as candidates for biomarkers for tissue specificity. The
commonality of the important roles bimodal genes play in tissue differentiation in both the human
and mouse indicates the potential value of mouse data in providing context for human tissue
studies. The regulation motifs enriched in the bimodal gene set (TATA boxes, alternative
promoters, methlyation) have known associations with complex diseases, such as cancer, providing
further potential for the use of bimodal genes in studying the molecular basis of disease.
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Background
Our recent work applied an automated high-throughput
method to classify genes with bimodal expression profiles
within the mouse genome based on microarray experi-
ments performed on healthy tissues using the Affymetrix
MGU74Av2 microarray platform [1]. The identification of
genes with bimodal expression is useful to identify the
biological variation of genes that are tightly regulated
around two discrete levels at the transcript level [2]. Many
of the bimodal genes were expressed in "high" or "low"
modes on a tissue-dependent basis. Enrichment analysis
using Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways [3] and Gene Ontology (GO) annota-
tion [4] within this set of bimodal genes revealed that they
are utilized in cell-cell communication and communica-
tion with the extracellular environment. We had also eval-
uated the expression of the bimodal genes in disease states
for diabetes types I and II to reveal some of these genes
with altered modes of expression in the disease state,
revealing the roles of these genes in cell communication
and immune response. As a natural extension of this
work, we have applied the same automated high-through-
put method to classify genes with bimodal expression in
the human genome and compared the list with human
orthologs of mouse bimodal genes. Moreover, we looked
into the transcript-level regulation of bimodal genes using
a variety of bioinformatics databases.
The detection of bimodal genes in human is useful for
determining a set of genes tightly controlled around two
states at the transcript level. Additionally, the identifica-
tion of these bimodal genes provides an indication of how
well the previous methods extend across species and dif-
ferent microarray platforms. While it is expected that
many orthologs between human and mouse would share
patterns of regulation such as bimodality, the literature
has also documented that many gene regulation promot-
ers have changed over the course of evolution between
human and mouse [5]. Genes with bimodal expression
profiles in both organisms may indicate conservation of
alternative promoters, which have been implicated in tis-
sue-specific expression common among the bimodal
genes. Alternately, genes with known orthologs that have
been identified as bimodal in only one of these species,
may illustrate the instability in mammalian promoters
[5,6]. Investigation of the regulatory mechanisms at play
in the expression of bimodal genes should provide insight
into the stability of their expression as well as how these
genes may lose regulation in the process of disease [7].
There are many factors contributing to the regulation of
transcription, having varying impact in the difference in
expression level and the time scale over which the expres-
sion level may change, either within a cell or over a course
of cell divisions. Transcription factors may enhance or
inhibit expression as they bind to regulatory gene promot-
ers effecting transcription initiation [8]. Changes in tran-
scription factor activity may account for bimodality in
genes within a single tissue over time, such as in circadian
rhythm pathways [9]. Transcript-level regulation may also
be achieved through epigenetic modification, such as
CpG island methylation, which inhibits transcription
either at the promoter region or downstream [10,11].
Additional epigenetic mechanisms, including histone
modifications such as methylation and acetylation were
shown to be associated with transcription initiation and
elongation [12]. These epigenetic regulatory mechanisms
may be linked with bimodality resulting from differenti-
ated tissues, where stable modifications maintain a high
mode of expression in a certain number of tissues, and a
low mode of expression in others. Regulatory mecha-
nisms mentioned above may work in combination to pro-
duce a variety of expression profiles, where even in
bimodal genes one mechanism may account for expres-
sion level changes within a single mode of expression and
an alternative regulatory mechanism may account for
expression level changes between modes of expression.
In this study, we extend our classification of bimodal
genes to the human genome. Our results indicate that a
sizable number of genes with bimodal expression in
mouse are also bimodal in human, with recurring roles of
cell-cell communication and communication with the
extracellular environment. Furthermore, the set of bimo-
dal genes identified by our method shows a strong con-
nection to epigenetic regulation, namely methylation of
histone tails in gene promoter regions.
Results
Identification of bimodal genes in the human genome
Microarray data for tissue types listed in table 1 (See Addi-
tional file 1 for dataset and sample accession numbers)
were used to identify bimodal genes in the human
genome. Two-component mixture analysis of the 13076
unique genes represented in both Affymetrix HGU133A
and HGU133plus2 microarrays identified 1847 genes, or
14%, as bimodal, with p < 0.001. Among these genes with
orthologs in mouse, 42% were identified in our previous
study on MGU74Av2 microarrays. The probability of
obtaining this overlap from a random selection of genes,
estimated from the hypergeometric distribution, is indis-
tinguishable from zero. Additional file 2 provides the list
of bimodal genes accompanied by the mouse ortholog, as
well as the p-value and threshold between high and low
modes of expression, XT.
Functional enrichment analysis highlights themes of cell 
communication
Enrichment of KEGG pathways and GO terms extended
the theme of communication with neighboring cells andBMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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the extracellular environment that was also evident from
bimodal genes in mouse. Enriched KEGG pathways are
presented in Table 2, while enriched GO terms are
detailed in Table 3, including listings for cellular compo-
nent, biological process, and molecular function terms. A
majority of the KEGG pathways previously identified as
enriched for bimodal genes in mouse were also signifi-
cantly enriched in humans (Table 2). The most highly
populated pathways common to bimodal human genes
and human orthologs for bimodal mouse genes are the
calcium signaling, focal adhesion and tight junction path-
ways. The cell communication pathways ECM-receptor
interaction and focal adhesion, which were identified as
significant within the last study, again appeared as highly
populated with bimodal genes. The KEGG ECM-receptor
interaction pathway is shown in Figure 1, with enriched
nodes highlighted in orange, and nodes replicated in the
mouse study outlined in bold. The figure shows that
integrin subunits a7, B1, and B6 and a subset of their
receptors including multiple collagen types I, II, and IV,
fibronectin and laminin are bimodal, as would be
expected since these proteins contribute to tissue specifi-
city. Also identified bimodal are the cell membrane recep-
tors CD44, SV2, CD36, and Syndecan. The KEGG focal
adhesion pathway, which also interacts with the ECM, is
depicted in Figure 2. The figure shows that the bimodal
genes are not only positioned at ECM and cell membrane
but also at different stages of cell signaling, indicating the
extensive role that bimodal genes play in the processing of
crosstalk between cells and the ECM. Proteins that are
deemed as bimodal in this pathway include EGF, ELK1,
FYN, HGF, vinculin, actinin and cyclins D1 and D2. Addi-
tional file 3 presents the list of bimodal genes along the
enriched KEGG pathways. Further enrichment analysis for
the sets of bimodal genes expressed in the "high" and
"low" modes was performed on three tissue types with the
most abundant samples. Enrichment of the "high" and
"low" mode subsets revealed tissue-specific activation and
deactivation, as may be expected for pathways and GO
terms describing specialized functions such as muscle
contraction or synaptic transmission. The KEGG pathways
listed in Table 4 and the GO terms listed in Table 5 dem-
onstrate the tissue-specific activation and deactivation of
bimodal genes and show consistency between human and
mouse for several terms.
Promoter analysis reveals bias for TATA boxes in bimodal 
genes
The mammalian promoter database (MPromDB) [13]
was used to assess the distribution of common promoter
types within the set of bimodal genes. MPromDB con-
tained promoters for 840 genes represented on the
HGU133 arrays and promoters for 536 genes represented
on the MGU74Av2 array. The frequencies of the common
promoter types AP-1, AP-2, SP1, TATA and CAAT are illus-
trated in Figure 3A and 3B for the sets of bimodal and
non-bimodal genes in human and mouse. The remaining
promoter types seldom appeared and were bundled
together into an "other" category. The set of bimodal
genes within human and mouse shows a statistically sig-
nificant bias for TATA promoters, with significance of p =
9.5e-5 for human and p = 4.9e-7 for mouse, estimated
from a hypergeometric distribution. The remaining pro-
moter types present between bimodal and non-bimodal
genes revealed no significant differences that were consist-
ent between human and mouse, suggesting that bimodal-
ity in gene expression is largely independent of the
regulatory promoter type. The SP1 and AP1 promoters
appeared underrepresented in mouse bimodal genes, but
this result is based on only a small subset of genes and was
not consistent with the results in human.
Alternative promoter sites more common in bimodal genes
The database of transcription start sites (DBTSS) [14] was
used to evaluate the number of alternative promoters
associated with genes in the bimodal and non-bimodal
subsets for human and mouse. The distribution of alterna-
tive promoters was shifted towards a higher number of
promoters per gene for those with bimodal distributions,
as shown in Figure 3C and 3D, providing evidence for
some contribution towards the dynamic range of gene
expression required for bimodality. When compared
Table 1: Microarray datasets used in this study representing 
normal human tissue.
Tissue Samples (Used in mouse study)
adipose 10 (6)
adrenal 10 (6)
brain 89 (89)
colon 10 (5)
epidermal 25 (25)
heart 38 (38)
kidney 10 (3)
liver 10 (8)
lung 26 (26)
mammary 15 (15)
muscle 64 (64)
ovary 10 (10)
pancreas 6 (5)
peripheral_blood 12 (12)
small_intestine 7 (3)
spleen 12 (12)
stomach 10 (1)
testis 38 (49)
thymus 5 (11)
total 407 (388)
The number of tissue samples used in the previous work that 
identified bimodal genes in mouse are included in parentheses. Sample 
accession numbers from GEO and ArrayExpress are listed in 
Additional File 1.BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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against non-bimodal genes, two or more promoters are
more common in bimodal genes for both human and
mouse, with a respective significance level of p ≈ 0 and p
= 1.9e-8, estimated from a hypergeometric distribution.
Multiple promoters per gene may be prevalent but not
required for bimodal expression. Alternative promoter
Table 2: KEGG pathway enrichment for human switch-like genes.
Human bimodal genes Mouse bimodal genes
KEGG Pathway Genes
Observed
Genes
Expected
Ration of
Enrichment
P-values Genes
Observed
Genes
Expected
Ration of
Enrichment
P-values
Tight junction 39 17.09 2.28 2.87E-07 30 14.60 2.05 4.52E-05
Cell adhesion 
molecules (CAMs)
36 16.81 2.14 4.31E-06 23 16.92 1.36 7.17E-02
Regulation of actin 
cytoskeleton
51 27.54 1.85 6.10E-06 27 25.38 1.06 3.95E-01
Focal adhesion 50 26.84 1.86 6.22E-06 43 23.89 1.80 4.77E-05
Calcium signaling 
pathway
44 23.31 1.89 1.54E-05 25 20.90 1.20 1.91E-01
Citrate cycle 
(TCA cycle)
11 3.53 3.12 2.85E-04 6 3.98 1.51 1.96E-01
Glycolysis/
Gluconeogenesis
18 7.91 2.28 4.64E-04 14 7.47 1.88 1.16E-02
PPAR signaling 
pathway
19 8.62 2.21 5.10E-04 17 9.46 1.80 9.09E-03
Long-term 
potentiation
20 9.32 2.15 5.47E-04 15 8.13 1.85 1.08E-02
Leukocyte 
transendothelial 
migration
28 15.11 1.85 7.12E-04 20 14.10 1.42 6.15E-02
Carbon fixation 9 2.97 3.03 1.29E-03 7 2.99 2.34 2.00E-02
Adherens junction 20 10.17 1.97 1.81E-03 13 10.12 1.28 2.02E-01
Gap junction 24 13.14 1.83 2.03E-03 16 10.95 1.46 7.02E-02
Melanogenesis 23 12.57 1.83 2.44E-03 14 12.94 1.08 4.19E-01
Type I diabetes 
mellitus
13 5.65 2.30 2.49E-03 11 7.80 1.41 1.44E-01
Alanine and 
aspartate 
metabolism
10 3.96 2.53 3.57E-03 6 3.65 1.64 1.44E-01
Neurodegenerative 
Diseases
12 5.23 2.30 3.67E-03 5 4.98 1.00 5.72E-01
MAPK signaling 
pathway
50 34.61 1.44 4.14E-03 36 31.36 1.15 2.04E-01
Reductive 
carboxylate cycle 
(CO2 fixation)
5 1.27 3.93 4.29E-03 2 1.66 1.21 5.13E-01
Endometrial cancer 14 7.06 1.98 7.76E-03 11 6.80 1.62 6.59E-02
Pyruvate 
metabolism
11 5.09 2.16 8.75E-03 7 4.81 1.45 1.94E-01
ECM-receptor 
interaction
20 11.58 1.73 8.98E-03 25 10.45 2.39 1.00E-05
Long-term 
depression
18 10.45 1.72 1.31E-02 17 9.12 1.86 6.16E-03
Cell 
Communication
25 16.10 1.55 1.53E-02 34 15.43 2.20 2.47E-06
Insulin signaling 
pathway
27 18.36 1.47 2.38E-02 26 15.93 1.63 6.19E-03
Fructose and 
mannose 
metabolism
7 4.94 1.42 2.17E-01 12 5.31 2.26 3.63E-03
Cysteine 
metabolism
2 2.12 0.94 6.47E-01 4 1.00 4.02 8.53E-03
KEGG pathways enrichment was computed using the set of human bimodal genes as well as previously identified bimodal genes in mouse. Pathways 
enriched with p ≤ 0.01 in both bimodal human genes and the set of bimodal mouse genes are shown in bold. Italicized values do not meet the p ≤ 
0.01 significance threshold.B
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Table 3: Gene ontology enrichment for human switch-like genes.
Human bimodal genes Mouse bimodal genes
Gene Ontology Genes
Observed
Genes
Expected
Ration of
Enrichment
P-values Genes
Observed
Genes
Expected
Ration of
Enrichment
P-values
CC Cytoplasm 527 408.92 1.29 0.00E+00 395 335.13 1.18 3.73E-05
cytoskeleton 110 57.49 1.91 0.00E+00 68 41.97 1.62 1.91E-05
sarcoplasmic reticulum 14 2.40 5.83 5.39E-10 10 2.49 4.02 2.06E-05
membrane 680 577.01 1.18 2.03E-08 494 442.64 1.12 9.12E-04
striated muscle thick filament 12 2.26 5.31 6.39E-08 7 1.99 3.52 1.25E-03
muscle myosin complex 12 2.54 4.72 4.94E-07 0 N/A N/A N/A
actin cytoskeleton 36 15.68 2.30 6.87E-07 11 8.13 1.35 1.78E-01
myosin complex 21 6.92 3.03 9.19E-07 13 5.81 2.24 2.76E-03
neuromuscular junction 6 0.85 7.08 7.89E-06 6 2.65 2.26 3.69E-02
cell junction 62 37.01 1.68 2.09E-05 55 28.20 1.95 2.64E-07
Z disc 9 1.98 4.55 2.24E-05 8 3.48 2.30 1.51E-02
synapse 41 22.04 1.86 4.26E-05 41 20.07 2.04 2.33E-06
membrane fraction 97 66.25 1.46 5.02E-05 32 27.71 1.15 2.10E-01
growth cone 10 2.68 3.73 8.41E-05 9 3.32 2.71 2.72E-03
plasma membrane 239 192.10 1.24 9.90E-05 169 143.67 1.18 9.51E-03
cell projection 23 11.02 2.09 3.38E-04 19 10.62 1.79 6.35E-03
costamere 4 0.57 7.08 3.97E-04 1 0.66 1.51 5.16E-01
clathrin coat of trans-Golgi network 
vesicle
6 1.27 4.72 4.51E-04 0 N/A N/A N/A
sarcoplasmic reticulum membrane 6 1.27 4.72 4.51E-04 5 1.16 4.31 1.95E-03
proteinaceous extracellular matrix 52 33.62 1.55 7.38E-04 60 28.04 2.14 1.47E-09
integral to plasma membrane 184 148.88 1.24 9.15E-04 53 47.62 1.11 2.14E-01
troponin complex 5 0.99 5.06 9.16E-04 6 1.33 4.52 4.27E-04
axon 10 3.81 2.62 2.62E-03 18 7.96 2.26 3.97E-04
sarcolemma 6 1.70 3.54 3.39E-03 13 3.82 3.41 1.51E-05
basement membrane 12 5.79 2.07 9.14E-03 17 5.81 2.93 1.12E-05
collagen 7 2.83 2.48 1.60E-02 14 4.81 2.91 7.34E-05
postsynaptic membrane 19 12.71 1.49 4.48E-02 21 10.29 2.04 6.69E-04
I band 2 0.42 4.72 5.42E-02 4 0.66 6.03 7.55E-04
synaptic vesicle membrane 1 0.28 3.54 2.63E-01 6 1.33 4.52 4.27E-04
basal lamina 2 1.13 1.77 3.15E-01 9 2.49 3.62 1.79E-04
BP muscle contraction 39 12.43 3.14 0.00E+00 10 2.82 3.55 9.66E-05
striated muscle contraction 21 4.10 5.13 0.00E+00 11 3.15 3.49 5.21E-05
cell adhesion 112 65.68 1.71 3.76E-09 81 44.63 1.81 1.67E-08
nervous system development 79 42.38 1.86 1.36E-08 33 22.40 1.47 1.19E-02
muscle development 29 10.03 2.89 2.95E-08 14 5.31 2.64 2.72E-04
sensory perception of sound 33 15.26 2.16 8.44E-06 5 4.98 1.00 5.72E-01
glycolysis 19 7.06 2.69 2.44E-05 15 6.97 2.15 2.11E-03
regulation of heart contraction 13 3.96 3.29 4.01E-05 9 3.48 2.58 4.07E-03
cytoskeleton organization and 
biogenesis
24 10.74 2.24 7.75E-05 26 13.11 1.98 2.72E-04B
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antigen processing and presentation of 
peptide antigen via MHC class I
7 1.41 4.96 8.99E-05 6 2.49 2.41 2.67E-02
dephosphorylation 24 10.88 2.21 9.77E-05 11 9.12 1.21 2.98E-01
regulation of muscle contraction 8 1.84 4.36 1.03E-04 13 2.82 4.61 8.48E-08
regulation of striated muscle contraction 6 1.13 5.31 1.71E-04 2 0.50 4.02 7.34E-02
central nervous system development 25 12.01 2.08 1.99E-04 5 4.81 1.04 5.39E-01
cell differentiation 72 47.88 1.50 1.99E-04 54 49.44 1.09 2.57E-01
multicellular organismal development 136 102.41 1.33 2.26E-04 84 85.11 0.99 5.73E-01
regulation of the force of heart 
contraction
5 0.85 5.90 2.96E-04 4 1.66 2.41 6.86E-02
neuromuscular synaptic transmission 5 0.85 5.90 2.96E-04 3 1.16 2.58 9.46E-02
neuron migration 12 4.10 2.93 3.05E-04 8 8.63 0.93 6.50E-01
neuron differentiation 13 4.66 2.79 3.08E-04 4 5.81 0.69 8.55E-01
glycogen metabolic process 12 4.24 2.83 4.44E-04 3 3.32 0.90 6.68E-01
protein amino acid dephosphorylation 29 15.54 1.87 5.06E-04 11 11.95 0.92 6.67E-01
tricarboxylic acid cycle 10 3.39 2.95 9.10E-04 6 3.65 1.64 1.44E-01
very-long-chain fatty acid metabolic 
process
5 0.99 5.06 9.16E-04 1 0.50 2.01 4.20E-01
ion transport 83 62.01 1.34 2.89E-03 67 44.13 1.52 1.88E-04
transport 218 188.15 1.16 8.19E-03 188 153.46 1.23 9.54E-04
calcium ion transport 20 11.72 1.71 1.03E-02 21 8.96 2.34 7.22E-05
synaptic transmission 35 24.01 1.46 1.28E-02 21 7.96 2.64 8.49E-06
MF actin binding 78 34.32 2.27 0.00E+00 42 27.04 1.55 1.76E-03
structural constituent of muscle 28 5.65 4.96 0.00E+00 5 1.49 3.35 8.74E-03
structural molecule activity 81 42.52 1.91 3.01E-09 58 34.01 1.71 1.53E-05
structural constituent of cytoskeleton 32 12.15 2.63 8.12E-08 22 11.45 1.92 1.26E-03
protein binding 777 677.86 1.15 1.68E-07 558 497.39 1.12 1.79E-04
calmodulin binding 37 16.95 2.18 1.93E-06 23 13.11 1.75 3.73E-03
motor activity 33 14.69 2.25 3.40E-06 28 13.60 2.06 7.77E-05
calcium ion binding 145 103.40 1.40 8.50E-06 116 76.98 1.51 1.37E-06
GTPase activity 43 24.15 1.78 8.61E-05 22 19.74 1.11 3.24E-01
phosphoprotein phosphatase activity 31 15.96 1.94 1.52E-04 10 13.44 0.74 8.85E-01
phosphoric monoester hydrolase activity 25 11.87 2.11 1.61E-04 12 10.12 1.19 3.07E-01
microfilament motor activity 9 2.40 3.75 1.82E-04 3 1.00 3.01 6.15E-02
NAD binding 13 4.52 2.88 2.14E-04 3 4.48 0.67 8.49E-01
transferase activity, transferring 
phosphorus-containing groups
7 1.55 4.51 2.17E-04 6 1.66 3.62 2.36E-03
protein tyrosine phosphatase activity 25 12.43 2.01 3.59E-04 14 10.62 1.32 1.65E-01
transporter activity 61 40.68 1.50 6.35E-04 41 33.18 1.24 8.24E-02
long-chain-fatty-acid-CoA ligase activity 6 1.41 4.25 9.92E-04 3 1.33 2.26 1.33E-01
creatine kinase activity 3 0.57 5.31 1.01E-02 4 0.66 6.03 7.55E-04
extracellular matrix structural constituent 18 10.88 1.65 1.96E-02 18 6.80 2.65 3.52E-05
ion channel activity 48 36.02 1.33 2.15E-02 46 25.38 1.81 2.17E-05
GO category enrichment was computed using the set of human bimodal genes as well as the previously identified bimodal genes in mouse. GO terms enriched with p ≤ 0.001 in both bimodal 
human genes and the set of bimodal mouse genes are shown in bold. Italicized values do not meet the p ≤ 0.001 significance threshold
Table 3: Gene ontology enrichment for human switch-like genes. (Continued)BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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sites in human and mouse were tested for tissue-selective
usage corresponding to the mode of expression for bimo-
dal genes. Alternative promoters for 168 bimodal genes in
human were identified as corresponding with the mode of
expression across within the nineteen tissues. Alternative
promoter data were not available for skeletal muscle tis-
sue in mouse, but data for the remaining 18 tissues iden-
tified 131 genes with at least one alternative promoter
corresponding to the mode of expression. Random per-
mutation of the tissue labels was used to estimate a
median false discovery rate of 4%. Though there was no
overlap between these tissue-selective promoter gene sets
in human and mouse, there were several pathways in
common for this comparison, including the neuroactive
ligand-receptor interaction, gap junction, and calcium sig-
naling pathway. The alternative promoters identified as
corresponding to the mode of expression in both human
and mouse were largely brain-specific. For example, the
genes GRIA2 in human and Gria1 in mouse encoding for
glutamate receptor proteins in the neuroactive ligand-
receptor interaction pathway were associated with multi-
ple alternative promoters specific to brain. Expression box
plots across the nineteen tissues having at least one pro-
moter specific to brain, is shown in Figure 3E and 3F for
human GRIA2 and mouse Gria1 genes, respectively. These
results indicate that multiple alternative promoters may
provide redundancy and that a single mode of expression
does not necessarily correspond with a unique alternative
promoter.
DNA methylation shows a negligible contribution to 
bimodal gene expression
Cytosine methylation has been shown to provide a stable
mechanism in mammals for altering DNA-protein inter-
actions [10]. Genes can be transcribed from methylation-
free promoters even when adjacent transcribed and non-
transcribed regions are extensively methylated [10]. Meth-
ylation of CpG-rich promoters prevents transcriptional
initiation and ensures the silencing of imprinted genes
and genes in the X Chromosome [10]. Recent data given
by Illingworth et al. [15] allowed us to investigate aspects
of epigenetic regulation for their contribution to bimodal
gene regulation. These authors surveyed methylation
within blood, brain, muscle, and spleen and obtained lists
of genes with methylated CpG islands in 5', intragenic,
and 3' regions, which mapped to roughly 6–8% of human
genes. The genes identified with intragenic DNA methyla-
tion were more common among the set of bimodal genes,
suggesting that the inhibitory effect of DNA methylation
on transcription elongation [11] may be a regulatory
mechanism for bimodal genes. We also used the methyl-
ation data from Illingworth et al. [15] to test the relation-
ship between DNA methylation status and the mode of
expression within bimodal genes. The results varied for
each tissue type, with the largest differences being
decreased DNA methylation in bimodal genes with a
"high" mode of expression in brain and increased DNA
methylation in bimodal genes with a "high" mode of
expression in muscle. DNA methylation is typically con-
sidered a gene silencing mechanism, which would corre-
Table 4: KEGG pathways enriched for bimodal genes with "high" or "low" expression within brain, heart, and skeletal muscle tissues in 
human and mouse.
Brain Heart Skeletal Muscle
Human Mouse Human Mouse Human Mouse
Calcium signaling pathway high
Carbon fixation high High high
Cell Communication low low high High high
Cell adhesion molecules (CAMs) low
Citrate cycle (TCA cycle) high high
ECM-receptor interaction low low high high high high
Focal adhesion low low high high high high
Gap junction high high low low low
Glycolysis/Gluconeogenesis high high high high
Insulin signaling pathway high
Leukocyte transendothelial migration high
Long-term depression high low low low low
Long-term potentiation high low
Neurodegenerative Diseases high
Pyruvate metabolism high high high
Reductive carboxylate cycle (CO2 fixation) high high
Regulation of actin cytoskeleton high
Type I diabetes mellitus low
The mode of expression is indicated for tissue types where pathways are significantly enriched for the set of bimodal genes in the "high" mode or 
the set of bimodal genes in the "low" mode of expression. Significance was determined from a hypergeometric distribution with cutoff p = 0.05.BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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Table 5: Gene Ontology terms enriched for bimodal genes with "high" or "low" expression within brain, heart, and skeletal muscle 
tissues in human and mouse.
Brain Heart Skeletal Muscle
Human Mouse Human Mouse Human Mouse
CC actin cytoskeleton high high high
axon high high low low low low
basal lamina low
basement membrane low high high
cell junction high high low low low
cell projection high high
collagen low low high high high
cytoplasm high high high
cytoskeleton low high high high high
growth cone high high low
I band high
integral to plasma membrane low
membrane high low
membrane fraction low low
muscle myosin complex low high
myosin complex low low high
plasma membrane low
postsynaptic membrane high high low low low
proteinaceous extracellular matrix low low high high high
sarcolemma low high high
sarcoplasmic reticulum low low high high high
striated muscle thick filament low high
synapse high high low low low low
synaptic vesicle membrane low
troponin complex low high high
Z disc low low high high high high
BP antigen processing and presentation of peptide antigen via MHC class I low high high
cell adhesion low high high high
cell differentiation high
central nervous system development high low
cytoskeleton organization and biogenesis high
glycogen metabolic process low high high
glycolysis high high high
ion transport high high low low
muscle contraction low low high high high
muscle development low high high
nervous system development high high low low
neuron differentiation high low
neuron migration high
regulation of heart contraction high high
regulation of muscle contraction low high
regulation of striated muscle contraction high
regulation of the force of heart contraction high high high
sensory perception of sound high high
striated muscle contraction low low high high
synaptic transmission high high low low low low
transport high high low low
tricarboxylic acid cycle high high high high
MF actin binding high high high
calcium ion binding high high high
extracellular matrix structural constituent low low high high high
GTPase activity high
ion channel activity high low low
microfilament motor activity high
NAD binding highBMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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protein binding low
structural constituent of muscle low low high high
structural molecule activity low high
The mode of expression is indicated for tissue types where terms are significantly enriched for the set of bimodal genes in the "high" mode or the 
set of bimodal genes in the "low" mode of expression. Significance was determined from a hypergeometric distribution with cutoff p = 0.05.
Table 5: Gene Ontology terms enriched for bimodal genes with "high" or "low" expression within brain, heart, and skeletal muscle 
tissues in human and mouse. (Continued)
ECM-receptor interaction pathway enriched by human switch-like genes Figure 1
ECM-receptor interaction pathway enriched by human switch-like genes. Nodes enriched for human bimodal genes 
are colored orange, while nodes also identified as bimodal in mouse orthologs are outlined in bold. In all, the overlap between 
bimodal human and bimodal mouse orthologs contains thirteen unique genes represented in seven unique nodes in the ECM-
receptor pathway. Nodes colored in gray were not identified as bimodal, while white nodes are used for genes that are not 
represented on the HGU133A array.BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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spond to low expression. However, the very small portion
of genes represented in the CpG island methylation data
for these four tissues may not be an adequate set to
observe a consistent trend.
Histone methylation provides a switching mechanism for 
bimodal genes
Next, we considered the possible role of epigenetic regula-
tion as a switching mechanism for bimodal genes. A
recent dataset that mapped histone modifications across
the human genome for three cell types, including human
embryonic H9 stem cells (hES), liver cells (hepatocytes),
and B-cell lymphocytes [12] was used to evaluate the
enrichment of histone 3 lysine 4 trimethylation
(H3K4me3) at the promoters of bimodal genes. The
H3K4me3 enrichment based on each of these three tissue
types did not suggest a role in the regulation of bimodal
genes (Figure 4A). However, if histone methylation pro-
vided a switching mechanism for bimodal gene expres-
sion, this would be evident in the differential methylation
between tissue types, and not methylation status pertain-
ing to a single tissue type. We used the data from these
three tissues to create lists of genes with differentially
enriched H3K4me3 regions for liver versus H9 hES cells
and for B-cells versus H9 hES cells. These sets of differen-
tially enriched H3K4me3 regions appeared with 50 to
100% higher frequency in bimodal genes compared to
non-bimodal genes, as seen in Figure 4A. To further inves-
tigate the correlation between histone methylation and
bimodal gene expression, we gathered additional micro-
array samples corresponding to H9 stem cells (GEO data-
set accession numbers GSE9865, GSE8884, and
GSE2248) and evaluated the mode of expression for
bimodal genes within those H9 stem cell samples as well
as liver samples within our dataset. We identified a group
of bimodal genes as I) "high" in liver but "low" in stem
cells, II) "low" in liver but "high" in stem cells, and III)
expressed in common modes between these two tissues
("high" in both or "low" in both). These results are plot-
ted in Figure 4B. Group I (green "+" symbols in Figure 4B)
KEGG Focal adhesion pathway enriched by human switch-like genes Figure 2
KEGG Focal adhesion pathway enriched by human switch-like genes. Nodes enriched for human bimodal genes are 
colored orange, while nodes also identified as bimodal in mouse orthologs are outlined in bold. In all, the overlap between 
human and mouse orthologs contains twenty-two unique genes represented in nine unique nodes in the focal adhesion path-
way. Nodes colored in gray were not identified as bimodal, while white nodes are used for genes that are not represented on 
the HGU133A array.BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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Summary of promoter usage between bimodal and non-bimodal subsets Figure 3
Summary of promoter usage between bimodal and non-bimodal subsets. The relative frequency of core promoter 
types cataloged in MPromDB [13] is shown for bimodal and non-bimodal gene subsets in A) human and B) mouse. The number 
of alternative promoters per gene is shown for bimodal genes and non-bimodal genes for C) human and D) mouse. For a sub-
set of bimodal genes with multiple alternative promoters, tissue-dependent alternative promoters from DBTSS [14] corre-
sponded to the mode of expression, as shown for glutamate receptors E) GRIA2 in human and F) Gria1 in mouse.BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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had a corresponding increase in methylation enrichment
for liver vs. stem cells for nearly 85% of the genes, while
group I (blue "x" symbols in Figure 4B) had a correspond-
ing decrease in liver vs. stem cells for 77% of the genes.
Approximately, 65% of the remaining bimodal genes
expressed in common modes between these two tissue
types (black points in Figure 4B) were within the standard
deviation around the line y = x. These results demonstrate
a strong association between histone methylation status
and the mode of expression for bimodal genes.
Discussion
In this study, using a large-scale microarray database, we
have annotated 1847 human genes as having bimodal
gene expression profiles. A recent study used again a large
human microarray dataset for cancer samples to identify
nearly 800 bimodal genes with the employment of a
model-based clustering algorithm [7]. A comparison of
their list against our list of bimodal genes resulted in 285
common elements, suggesting that bimodal genes in our
list may not perform as bimodal in disease states in addi-
tion to possible switching of expression state in a disease
state from one mode to another. Even in healthy tissue
comparison, orthology argument did not entirely preserve
bimodality in mouse and human data. Nearly 40% of the
genes in this list corresponded to human orthologs of
mouse bimodal genes that were annotated in our previous
study [1]. Bimodality within 40% of human-mouse
orthologs can be viewed as substantial overlap when con-
sidering that besides measurement noise and slightly dif-
ferent tissue types represented by datasets for each
organism, differences exist in transcript sequences and
transcript regions targeted by the microarray probes for
orthologous genes among the two species. Further differ-
ences in gene expression between the two species arise
from changes in regulatory sequences resulting from evo-
lution [5,6]. This overlap demonstrates some degree of
stability of bimodality in these datasets, even though we
did not force identical tissue type quantities between the
two organisms.
Our study shows that bimodal genes make a large contri-
bution to the proteins composing the extracellular matrix
as well as external membrane proteins. The enrichment
within GO cellular component terms may at first appear
contradictory, since the results include disparate terms
related to the plasma membrane, cytoplasm, and extracel-
lular matrix, while the KEGG pathway findings more
highlighted extracellular communication. However, GO
terms do not have a direct correspondence with KEGG
Bimodal gene enrichment for promoter region methylation of lysine 4 of histone H3 (H3K4me3) Figure 4
Bimodal gene enrichment for promoter region methylation of lysine 4 of histone H3 (H3K4me3). A) Fraction of 
bimodal vs. non-bimodal genes enriched for histone methylation within their promoters as reported by Guenther et al. [12] for 
H9 hES cells, liver (hepatocytes), and B-cells. The fourth and fifth sets of bars represent the set of genes enriched at high confi-
dence within one tissue but not the other liver versus hES cells and B-cell versus hES cells. B) H3K4me3 enrichment ratio from 
Guenther et al. [12] for liver vs. stem cells is shown for bimodal genes. Genes expressed with "high" mode in liver and "low" 
mode in H9 stem cells are shown with green "+" symbols, while bimodal genes expressed with "low" mode in liver and "high" 
mode in stem cells are shown with blue "x" symbols. Black points are used for the remaining bimodal genes expressed in com-
mon modes between these two tissue types. The standard deviation around the line y = x (solid red line) is shown as dashed 
red lines.BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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pathways and gene membership is not exclusive to a sin-
gle term. Mapping KEGG pathways to GO cellular compo-
nent reveals that 66% of the bimodal genes in Focal
Adhesion are contained in the cytoplasm; 40% of genes in
both ECM-receptor interaction and Focal adhesion are
contained in the GO cellular component "plasma mem-
brane." Within the cell membrane side of the ECM-recep-
tor interaction pathway, integrin subunits α7, β1, and β6
were identified as bimodal, while several others, includ-
ing α2–α6 and β3–β5 were not. This finding suggests that
integrin complexes are regulated by an interplay of tran-
script-level regulation as well as previously shown post-
translational modifications [16,17]. In addition, several
bimodal genes in the focal adhesion pathway are linked to
phosporylation of β-catenin, a key element in the Wnt –
signaling pathway, which plays a functional role in cell
fate, proliferation, and apoptosis [18]. The Wnt-signaling
pathway is active in development and is also a culprit in
disease such as colorectal cancer and melanomas [18,19].
As such, bimodal genes upstream from these interactions
provide potential markers for tissue-specific signaling as
well as metabolic and chronic diseases.
Functional enrichment analysis of "high" and "low"
expression subsets of the bimodal genes reveals that they
play a role of activation and deactivation of tissue-specific
pathways (table 4) and processes (Table 5). Bimodal gene
sets involved in the Focal adhesion and ECM-receptor
pathways demonstrated consistent modes of expression
across human and mouse for brain, heart, and skeletal
muscle, the three tissue types with the largest amount of
samples in our investigation (Table 4). GO enrichment
for "high" and "low" mode gene sets showed consistency
between tissue-specific modes of expression in human
and mouse, demonstrated by biological processes such as
synaptic transmission in brain, and muscle contraction in
skeletal muscle (Table 5). The consistency in expression
modes of bimodal genes in the mouse and human is fur-
ther reinforced by brain-specific expression for the cellular
components of synapse, post-synaptic membrane, and
muscle-specific expression for structural components of
muscle, such as sarcoplasmic reticulum, collagen, and
cytoskeleton (Table 5). Taken together, these findings
indicate that the mode of expression for bimodal genes
plays a role in the stable differentiation of specialized tis-
sues, and pathway-specific usage of these genes is con-
served across human and mouse in several cases.
Bimodality implies a high degree of transcript-level regu-
lation, and bimodal genes may act as switches for the
direction of signals and/or metabolic flow. Our study
shows that bimodality appears to arise independently
from the type of promoter present, even though we esti-
mate the number of TATA boxes in bimodal genes is
enriched, appearing in over 80% of bimodal genes with
documented promoter sites. This may merely reflect a bias
in gene annotation, as the involvement of these genes
among pathways of interest, such as MAPK signaling and
ECM-receptor interaction, may draw more focus for exper-
imentation. The number of alternative (promoter) tran-
scription start sites appears to have an influence on the
bimodality of gene expression. Unlike the limited number
of experimentally produced promoter binding sites, alter-
native promoter sites have been assessed by genome-wide
mapping of transcript 5' ends [14]. While the number of
known alternative promoter start sites for bimodal genes
is shifted to a higher number than for non-bimodal genes,
it is not sufficient to explain the phenomenon of bimodal-
ity. Additionally, previous studies investigating the usage
of alternative promoters by gene ontology cellular compo-
nent reveal that genes with several alternative promoters
play a role in signaling, but do not contribute to the extra-
cellular region, suggesting a difference from the set of
bimodal genes [20]. This still allows for bimodal genes to
include a subset of genes with a higher than average
number of alternative promoters that work in concert
with other regulatory mechanisms such as DNA methyla-
tion and histone modification.
We have shown that bimodal gene expression has a bias
for multiple alternative promoters, as well as an associa-
tion with histone methylation (H3K4me3), though a
complete description of the links between all possible reg-
ulatory mechanisms cannot be made with currently avail-
able data. A recent study has shown that CpG-specific
RNA polymerase II binding, associated with transcription
initiation, is conserved among different tissue types [21].
A large portion of these may constitute the set of house-
keeping genes, while others may appear at high modes of
expression in some tissues, while silenced in other tissues
via CpG methylation. A link has also been demonstrated
between DNA methylation and histone methylation,
where genes that undergo transcription initiation require
H3K4 methylation as well as unmethylated DNA [22,23].
Consistent with our findings in this study, H3K4 trimeth-
ylation was previously associated with transcriptionally
active genes [24]. The presence or absence of this modifi-
cation can achieve switch-like regulation [25,26]. Histone
methylation, along with DNA methylation, is a key player
in cell differentiation during development and maintain
cell lineage [15,27]. This stable regulation also maintains
the balance between cell communication molecules and
the extracellular environment [28]. Aberrant histone
methylation patterns are among the epigenetic modifica-
tions that give rise to cancer [29]. As the mode of expres-
sion for bimodal genes is closely related to H3K4me3
status, gene expression levels may be used as a surrogate
for detecting aberrant patterns of methylation associated
with disease. While our knowledge of methylation associ-
ated with gene regulation may be incomplete, genes regu-BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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lated through alternative promoters have an additional
layer of complexity, as they can have largely different
methylation status at individual promoters from tissue to
tissue [30]. The regulatory mechanism for bimodal genes
may therefore include a complex logic of DNA and his-
tone methylation among alternative promoters, in addi-
tion to positive and negative regulation through
transcription factor binding.
Alternative splicing events may present another explana-
tion for bimodality in the expression of genes. Alternative-
splicing isoforms have been identified as tissue-specific
[31]. A substantial portion of alternative splicing isoforms
are also associated with nonsense-mediated mRNA decay
[32]. Three out of five genes identified with muscle-spe-
cific alternative splicing in Xu et al. [31] (PDLIM7, TPM2,
and FHL1) were identified as bimodal and expressed in
"high" mode in our microarray data for muscle but not
other tissues. Five out of the twenty-two genes identified
as having brain-specific alternative splicing in Xu et al.
[31], were identified as having bimodal expression, but
only one of these (CDC42) was expressed in a brain-spe-
cific manner. This indicates the possibility that stable tran-
script splice isoforms account for the high mode of
expression in specific tissues, while alternative splice iso-
forms undergo nonsense-mediated decay. The methyla-
tion/promoter analysis presented here is a first step
towards understanding the complex interplay of various
molecular mechanisms affecting transcription in human
and mouse genomes.
Conclusion
This research expanded our representation of "switch-
like" gene expression by cataloging the bimodal genes evi-
dent in human microarray data for diverse tissue types.
Results obtained from human data affirm that genes with
bimodal, switch-like expression play a large role in cells
communication with the extracellular environment. Tis-
sue-specific modes of expression among the bimodal
genes organized by KEGG pathways and GO cellular com-
ponent revealed that they play a role in tissue specializa-
tion that is in common between human and mouse.
Equally as important, our results indicate bimodal genes
capture epigenetic aspects of gene regulation, indicative of
gene expression levels that are stable across cell divisions.
These findings verify that biologically relevant informa-
tion can be inferred from bimodal distributions, much in
the way that housekeeping genes have been used. Because
the "high" mode of expression modes corresponds well
with histone methylation enrichment in promoter
regions, bimodal genes may serve as biomarkers for com-
plex diseases such as cancer, where aberrant histone meth-
ylation is a known factor in disease progression. Through
the identification of condition-specific modes of expres-
sion within healthy tissue and disease subtypes, the
method presented allows for an alternative approach to
differential gene expression analysis.
Methods
Data Selection
Human gene expression microarray datasets were
obtained from both the Gene Expression Omnibus
(GEO) [33,34] and ArrayExpress [35,36] online repositor-
ies. For the purpose of comparing a subset of human
bimodal genes with those identified in mouse, we created
a microarray dataset with comparable tissue samples to
those used in the mouse study (Table 1) [1]. In order to
adequately represent some tissue types, it was necessary to
combine datasets from Affymetrix HGU133A and
HGU133plus2 arrays, which have 22,277 probesets in
common.
Microarray normalization
Affymetrix probe intensities were filtered to exclude
probesets that are not shared between the HGU133A and
HG133plus2 microarrays. The remaining probesets were
normalized using Robust Multichip Average (RMA) back-
ground correction, quantile normalization, and summari-
zation approach for large datasets described as the refRMA
algorithm [37]. RMA background adjustment was per-
formed on each chip. Quantile normalization was per-
formed by computing probe-level quantiles from a 940-
array (HGU133plus2) training set (Additional File 1) and
applying these quantiles to additional HGU133A arrays as
they were added to the dataset. RMA summarization was
performed by median polishing on the 940-array training
set and storing the row effects (probe effects) to be applied
to additional arrays as they were added to the dataset. The
quantile normalization and row effect vectors are pro-
vided in Additional File 1.
Gene annotation
Annotation for Entrez Gene ID, EMBL accession, gene
symbol, and gene ontology biological process, cellular
component, and molecular function were retrieved from
the HGU133plus2 and MGU74Av2 annotation files
updated March 2008 on the Affymetrix website [38].
KEGG pathway descriptions were retrieved April 29th,
2008 from the KEGG ftp site [3,39]. Orthologous gene
pairs between mouse and human were identified using
the EMBL accession number database from OMA browser
[40,41], dated November 2007, in addition to matching
official gene symbols. The data were then imported to
Matlab R2007b (The Mathworks Inc., Natick, MA, USA),
where all subsequent procedures were implemented.
Identification of bimodal genes in the human genome
Bimodal genes were identified in the human genome by
fitting a two-component mixture model, as detailed in the
methods of our previous work [1]. Briefly, we tested theBMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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hypothesis H1 that gene expression distribution follows a
two-component (bimodal) mixture against the hypothe-
sis H0 of a single normal distribution, adjusted for skew-
ness using a box-cox transformation. The log likelihood
ratio test statistic -2logλ was computed for the two-com-
ponent mixture hypothesis H1 versus the null hypothesis
H0  of a single component. Candidates for bimodal
"switch-like" genes were selected as those with p-values
no more than 0.001 based on a chi-square distribution
with six degrees of freedom at the values of -2logλ. This
subset of genes was further reduced by the imposing the
requirement that the standardized area of intersection A
was less than 0.10. We define A as the area of overlap
between the two components, representing type I and
type II error for the estimated bimodal distribution,
divided by the total area. A typical two-component repre-
sentation of bimodal gene expression is depicted in Figure
5. To verify that chip effect differences between the
HGU133plus2 and HGU133A did not influence the iden-
tification of bimodal genes, this procedure was applied to
the subset of samples both including and excluding
HGU133A arrays. Muscle tissue was selected for this due
to the large number of samples and the roughly equal por-
tions of HGU133plus2 and HGU133A arrays for this tis-
sue type. Bimodal expression patterns were identified
within muscle tissue first for the HGU133plus2 samples,
then for all muscle samples, which adds in potential chip
effects as well as lab effects. Identification of bimodal pro-
files within these samples demonstrated consistency
across array types, as classification was consistent for 97%
of probesets.
Functional enrichment analysis
KEGG pathway and GO annotations described above
were used to compute functional enrichment scores for all
switch-like genes. Functional enrichment analysis was
Bimodal gene expression Figure 5
Bimodal gene expression. The histogram and normal mixture probability density function (pdf) are shown for a typical 
bimodal gene. The threshold between the high and low mode of expression is labeled as XT and darker shading is used to rep-
resent the misclassification region.BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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performed in Matlab by calculating the ratio of genes
belonging to a functional category within a gene set of
interest against the total number of genes belonging to
that functional category within the 22,277 common
probesets between the HGU133A and HGU133plus2
arrays. Enrichment p-values were computed from a hyper-
geometric distribution [42]. The p-value cutoffs were
selected at 0.01 for KEGG pathways and 0.001 for GO
terms, to reduce the false discovery rate. The set of candi-
date bimodal genes was distributed among 186 unique
KEGG pathways and 618 unique GO cellular component
terms, for which an expected 1.9 and 0.6 of the terms may
appear significant by chance at these p-value cutoffs,
respectively. Functional enrichment analysis was repeated
within the list of significant terms to identify tissue-spe-
cific behavior within brain, heart, and muscle tissue.
These three tissues were selected because they are repre-
sented by a large number of samples within the data, and
several terms that should be specific to these tissue types
were identified as significantly enriched. Using the bino-
mial distribution approach detailed in [1], we identified
bimodal genes that were expressed either "high" or "low"
within these three tissue types. KEGG pathway and GO
subsets were tested for enrichment for sets of "high" and
"low" mode genes against the hypergeometric distribu-
tion with p = 0.05.
Promoter analysis
The set of bimodal genes was evaluated for regulatory
mechanisms including the core promoter type and the
number of alternative promoters. Genes were separated
into subsets of bimodal and non-bimodal for promoter
analysis to evaluate differences within each of human and
mouse. Promoter sites and sequence motifs were obtained
from MPromDB [13]. Promoters corresponding to the tar-
gets of transcription factors were mapped to the sets of
bimodal and non-bimodal genes using Entrez gene ID.
The remaining promoter types seldom appeared and were
bundled together into an "other" category. The frequency
that each of these regulatory sites, including AP-1, AP-2,
SP1, TATA and CAAT-signal, appear within bimodal genes
and non-bimodal genes was assessed for the bimodal and
non-bimodal subsets in human and mouse. Additional
annotation for human and murine genes describing the
number of alternative promoter sites (hspromoter.tab for
human and mmpromoter.tab for mouse, both dated June
12th, 2007) were downloaded from the database of tran-
scriptional start sites (DBTSS) [14]. The distribution of
alternative promoters was computed as a histogram
within the sets of bimodal genes and non-bimodal genes
within human and mouse. The statistical significance for
two, three, four, and two or more promoters was esti-
mated using the hypergeometric distribution.
Analysis of DNA methylation effect on mode of expression
DNA methyaltion was explored as a regulatory mecha-
nism for bimodal genes due to its known association with
gene silencing. CpG methylation data were obtained from
Illingworth at al.; supplementary information Dataset S1
[15]. This dataset documents methylation sites for
roughly 8% of the human genome across four tissues –
blood, brain, muscle, and spleen. The frequency of meth-
ylation sites that were mapped to 5', 3', and intragenic
regions of known genes was computed and significance of
enrichment within bimodal genes was estimated from the
hypergeometric distribution. This methylation data were
also used to evaluate correspondence between methyla-
tion status within either the 5' or intragenic regions and
the mode of expression in bimodal genes. Genes were
assigned to a mode of expression within each of the four
tissues by treating expression measurements within each
tissue as Bernoulli trials against the binomial distribution,
as described in [1]. The frequency of DNA methylation
was then calculated in the subsets of "high" and "low"
genes for each of the four tissues.
Comparison of histone methylation enrichment versus 
mode of expression
The final regulatory mechanism that was assessed for a
contribution to bimodal gene expression was histone
methylation. Methylation data were obtained from Guen-
ther et al. Table S3 and Table S4, which describes
H3K4me3 enrichement scores and locations across the
human genome for three cell types: human embryonic
stem cells (hES), liver cells (hepatocytes), and B-cell lym-
phocytes [12]. Enrichment scores for H3K4me3 desig-
nated as high-confidence in Guenther et al. were used to
create a gene set for each of these three tissue types [12].
Two additional gene sets were created based on differen-
tial H3K4me3 enrichment for liver versus H9 hES cells
and for B-cells versus H9 hES cells. For example, the liver
versus H9 hES gene set includes those enriched with high
confidence in liver but not H9 hES cells in addition to
those with high confidence in H9 hES cells but not liver.
The frequency of histone methylation sites based on these
three tissues as well as the differentially enriched sites
were evaluated for the sets of bimodal genes and non-
bimodal genes within human. Additionally, the signifi-
cance of each list of sites was evaluated using the hyperge-
ometric distribution.
To further investigate the interplay between histone meth-
ylation and bimodal gene expression, we gathered addi-
tional microarray samples corresponding to H9 stem cells
(samples GSM249282, GSM225045, and GSM38629,
from datasets GSE9865, GSE8884, and GSE2248, respec-
tively) and evaluated the mode of expression for bimodal
genes within that those H9 stem cells as well as liver sam-BMC Genomics 2008, 9:628 http://www.biomedcentral.com/1471-2164/9/628
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ples within our dataset. Using the binomial distribution
approach detailed in [1], we identified a group of bimodal
genes as I) "high" in liver but "low" in stem cells, II) "low"
in liver but "high" in stem cells, and III) expressed in com-
mon modes between these two tissues ("high" in both or
"low" in both). These three subsets were then used to cre-
ate a scatter plot of H3K4me3 enrichment, excluding
genes with enrichment scores below a 2-fold enrichment
in both hES and hepatocytes.
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